FEMY Femasys
- 1.2700
- -0.0600-4.51%
- 1.2600
- -0.0100-0.79%
Femasys News
Femasys Releases Updated Investor Presentation Information
Femasys: A Buy Rating on Innovative Reproductive Solutions and Market Expansion Potential
Femasys Price Target Maintained With a $12.00/Share by Chardan Capital
Femasys Price Target Maintained With a $12.00/Share by Chardan Capital
Femasys Is Maintained at Buy by HC Wainwright & Co.
Femasys Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Femasys, Raises Price Target to $12
HC Wainwright & Co. analyst Emily Bodnar maintains Femasys (NASDAQ:FEMY) with a Buy and raises the price target from $10 to $12.
Femasys Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
Femasys Q4 EPS $(0.19) Beats $(0.21) Estimate, Sales $213.11K Miss $240.00K Estimate
Femasys (NASDAQ:FEMY) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.21) by 9.52 percent. This is a 20.83 percent increase over losses of $(0.24) per s
Femasys GAAP EPS of -$0.93, Revenue of $1.07M
Press Release: Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update
Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update Following FDA Clearance of FemaSeed(R), Company Secures Capital to Support Commercial Initiatives; C
Analysts Offer Insights on Healthcare Companies: Femasys (FEMY) and NextCure (NXTC)
Express News | Chardan Capital Reiterates Buy on Femasys, Maintains $12 Price Target
Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape
Femasys Inc. (NASDAQ: FEMY) invites investors to join management in a Fireside Chat with Jones Trading Analyst Catherine Novack to discuss the current treatment landscape for infertility treatment in women.
Femasys Is Maintained at Buy by JonesTrading
Femasys Is Maintained at Buy by JonesTrading
Femasys Price Target Raised to $10.00/Share From $7.00 by JonesTrading
Femasys Price Target Raised to $10.00/Share From $7.00 by JonesTrading
Analysts Are Bullish on Top Healthcare Stocks: Femasys (FEMY), BioNTech SE (BNTX)
Express News | HC Wainwright & Co. Reiterates Buy on Femasys, Maintains $10 Price Target
Femasys Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/21/2024 443.48% HC Wainwright & Co. → $10 Reiterates Buy → Buy 11/14/2023 443.48% HC Wainwright & Co. $
JAGX and GNPX Among Health Care Movers
Express News | Femasys Announces Topline Data From Pivotal Trial For FemaSeed For Treatment Of Infertility; Says In The Severe Male Factor Cohort, Findings Show 24% Of Women Became Pregnant After FemaSeed, FemaSeed Pregnancy Rate By Cycle Was More Than Double Historic I
Femasys Announces Positive Topline Data From Pivotal Trial for Its FDA-Cleared FemaSeed for the Treatment of Infertility
Femasys Inc. (NASDAQ:FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, today announces topline data from its FemaSeed Localized Directional Insemination for artificial insemination pivotal trial (NCT04968847).
Analysis
Price Target
No Data
